Skip to content

Finished goods at other companies

Avanos Medical logo
Avanos MedicalAVNS
$78.2M+4.5%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$21.2M
AtriCure logo
AtriCureATRC
$34.66M+11.5%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s finished goods?
Pacira BioSciences, Inc. (PCRX) reported finished goods of $70.68M in Q1 2026.
How has Pacira BioSciences, Inc.'s finished goods changed year-over-year?
Pacira BioSciences, Inc.'s finished goods increased by 27.2% year-over-year, from $55.58M to $70.68M.
What is the long-term trend for Pacira BioSciences, Inc.'s finished goods?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s finished goods has grown at a 30.5% compound annual growth rate (CAGR), from $21.5M to $81.33M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.